Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
Titel:
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
Auteur:
Jabbour, Elias Gökbuget, Nicola Advani, Anjali Stelljes, Matthias Stock, Wendy Liedtke, Michaela Martinelli, Giovanni O’Brien, Susan Wang, Tao Laird, A. Douglas Vandendries, Erik Neuhof, Alexander Nguyen, Kevin Dakappagari, Naveen DeAngelo, Daniel J. Kantarjian, Hagop